FDA Approval Alert: The Need-to-Know | Zolbetuximab/Chemotherapy in Advanced CLDN18.2+ Gastric/GEJ Adenocarcinoma

In October 2024, the FDA approved zolbetuximab-clzb plus fluoropyrimidine- and platinum-based chemotherapy as frontline therapy for patients with locally advanced unresectable or metastatic HER2-negative, Claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma.

Zolbetuximab’s Impact on Gastric/GEJ Adenocarcinoma

Article

By ONCOLOGY Staff

Dec 6, 2024 9:00 PM

John Marshall, MD, discussed zolbetuximab, which the FDA recently approved for patients with CLDN18.2–positive locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.

Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.

Different Treatment Algorithms for Gastric Cancers May Improve Outcomes

Video

Oct 27, 2024 4:00 PM

Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.

Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.

Zolbetuximab/Chemo Displays PFS, OS Benefits in Gastric Cancer Trials

Video

By John L. Marshall, MD

Oct 24, 2024 8:00 PM

Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.

The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.

Zolbetuximab Has Benefit in Targeting CLDN18.2 in Gastrointestinal Cancers

Video

By John L. Marshall, MD

Oct 24, 2024 12:00 PM

The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.